CN1177834C - 二羟基己酸衍生物 - Google Patents

二羟基己酸衍生物 Download PDF

Info

Publication number
CN1177834C
CN1177834C CNB998027138A CN99802713A CN1177834C CN 1177834 C CN1177834 C CN 1177834C CN B998027138 A CNB998027138 A CN B998027138A CN 99802713 A CN99802713 A CN 99802713A CN 1177834 C CN1177834 C CN 1177834C
Authority
CN
China
Prior art keywords
methyl
benzyl
dihydroxyl
carboxylic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998027138A
Other languages
English (en)
Chinese (zh)
Other versions
CN1290255A (zh
Inventor
Jc
J·C·卡思
M·F·布朗
C·S·波斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1290255A publication Critical patent/CN1290255A/zh
Application granted granted Critical
Publication of CN1177834C publication Critical patent/CN1177834C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
CNB998027138A 1998-02-05 1999-01-18 二羟基己酸衍生物 Expired - Fee Related CN1177834C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7380198P 1998-02-05 1998-02-05
US60/073,801 1998-02-05

Publications (2)

Publication Number Publication Date
CN1290255A CN1290255A (zh) 2001-04-04
CN1177834C true CN1177834C (zh) 2004-12-01

Family

ID=22115885

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998027138A Expired - Fee Related CN1177834C (zh) 1998-02-05 1999-01-18 二羟基己酸衍生物

Country Status (36)

Country Link
EP (1) EP1051405B1 (OSRAM)
JP (1) JP3693916B2 (OSRAM)
KR (1) KR100385529B1 (OSRAM)
CN (1) CN1177834C (OSRAM)
AP (1) AP992A (OSRAM)
AR (1) AR016175A1 (OSRAM)
AT (1) ATE337307T1 (OSRAM)
AU (1) AU752407B2 (OSRAM)
BG (1) BG104726A (OSRAM)
BR (1) BR9907655A (OSRAM)
CA (1) CA2320388C (OSRAM)
DE (1) DE69932920T2 (OSRAM)
DZ (1) DZ2717A1 (OSRAM)
EA (1) EA003137B1 (OSRAM)
ES (1) ES2268847T3 (OSRAM)
GT (1) GT199900011A (OSRAM)
HR (1) HRP20000529B1 (OSRAM)
HU (1) HUP0100832A3 (OSRAM)
IL (1) IL137330A0 (OSRAM)
IS (1) IS5562A (OSRAM)
MA (1) MA26603A1 (OSRAM)
MY (1) MY133125A (OSRAM)
NO (1) NO20003965D0 (OSRAM)
NZ (1) NZ505724A (OSRAM)
OA (1) OA11448A (OSRAM)
PA (1) PA8467301A1 (OSRAM)
PE (1) PE20000243A1 (OSRAM)
PL (1) PL342817A1 (OSRAM)
SK (1) SK11262000A3 (OSRAM)
TN (1) TNSN99013A1 (OSRAM)
TR (1) TR200002248T2 (OSRAM)
TW (1) TW470744B (OSRAM)
UA (1) UA57824C2 (OSRAM)
WO (1) WO1999040061A2 (OSRAM)
YU (1) YU47100A (OSRAM)
ZA (1) ZA99873B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360672A1 (en) * 1999-01-29 2000-08-03 Wayne W. Hancock Methods for preventing graft rejection and ischemia-reperfusion injury
EP1204643B1 (en) * 1999-08-20 2008-06-04 Dow AgroSciences LLC Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP1498417A1 (en) * 2000-02-04 2005-01-19 Pfizer Products Inc. Heterocyclic amide derivatives
PL357094A1 (en) 2000-02-04 2004-07-12 Pfizer Products Inc. Heterocyclic amide derivatives
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2448825C (en) 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
JP2005527604A (ja) * 2002-05-14 2005-09-15 ファイザー・プロダクツ・インク ジヒドロフラン２オン誘導体の製造方法
WO2003095440A1 (en) 2002-05-14 2003-11-20 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
ES2333318T3 (es) 2002-08-12 2010-02-19 Bend Research, Inc. Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
BR0313378A (pt) * 2002-08-12 2005-07-12 Pfizer Producs Inc Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923864A (en) * 1987-12-15 1990-05-08 Pfizer Inc. Certain heterocyclic-hexanamides useful for treating hypertension
ATE220661T1 (de) * 1994-10-19 2002-08-15 Novartis Erfind Verwalt Gmbh Antivirale ether von aspartat-protease-substrat- isosteren
DE19708106A1 (de) * 1997-02-28 1998-09-03 Bosch Gmbh Robert Einrichtung und Verfahren zur Information über Verkehrsstörungen

Also Published As

Publication number Publication date
DE69932920D1 (de) 2006-10-05
WO1999040061A2 (en) 1999-08-12
UA57824C2 (uk) 2003-07-15
HUP0100832A3 (en) 2002-03-28
PL342817A1 (en) 2001-07-02
IS5562A (is) 2000-07-14
CA2320388C (en) 2005-05-03
AP9901457A0 (en) 1999-03-31
NO20003965D0 (no) 2000-08-04
ZA99873B (en) 2000-08-04
TNSN99013A1 (fr) 2005-11-10
JP2002502839A (ja) 2002-01-29
IL137330A0 (en) 2001-07-24
NO20003965L (OSRAM) 2000-10-03
GT199900011A (es) 2000-07-20
BR9907655A (pt) 2000-10-24
YU47100A (sh) 2002-11-15
EP1051405A2 (en) 2000-11-15
KR100385529B1 (ko) 2003-05-27
DZ2717A1 (fr) 2003-09-01
HUP0100832A2 (hu) 2002-02-28
EA200000741A1 (ru) 2001-02-26
AP992A (en) 2001-08-06
EP1051405B1 (en) 2006-08-23
PE20000243A1 (es) 2000-04-07
WO1999040061A3 (en) 1999-10-21
MA26603A1 (fr) 2004-12-20
CN1290255A (zh) 2001-04-04
OA11448A (en) 2003-11-18
DE69932920T2 (de) 2007-02-08
HK1034969A1 (en) 2001-11-09
CA2320388A1 (en) 1999-08-12
BG104726A (en) 2001-04-30
TW470744B (en) 2002-01-01
PA8467301A1 (es) 2000-05-24
KR20010040684A (ko) 2001-05-15
TR200002248T2 (tr) 2000-12-21
EA003137B1 (ru) 2003-02-27
AU1778999A (en) 1999-08-23
ATE337307T1 (de) 2006-09-15
JP3693916B2 (ja) 2005-09-14
ES2268847T3 (es) 2007-03-16
MY133125A (en) 2007-10-31
NZ505724A (en) 2003-02-28
AU752407B2 (en) 2002-09-19
HRP20000529B1 (en) 2004-12-31
SK11262000A3 (sk) 2001-01-18
HRP20000529A2 (en) 2001-08-31
AR016175A1 (es) 2001-06-20

Similar Documents

Publication Publication Date Title
CN1177834C (zh) 二羟基己酸衍生物
HUP0001319A2 (hu) Heteroaril-hexanolsav-amid származékok, azok előállítása és szelektív inhibitorokként történő alkalmazása az MIP-1alfa saját CCR1 receptoraihoz való kapcsolódásának megakadályozására
CN1443172A (zh) 新的杂芳基衍生物及其作为药物的应用
KR20050021497A (ko) 피페리딘 유도체 및 ＭＩＰ-1α 수용체 ＣＣＲ1에결합하는 ＭＩＰ-1α의 선택적 길항제로서의 그들의 용도
US20040097554A1 (en) Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US6673801B1 (en) Dihydroxyhexanoic acid derivatives
JP2003522164A (ja) ヘテロ環式アミド誘導体
HK1034969B (en) Dihydroxyhexanoic acid derivatives
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
US20040087571A1 (en) Methods of using CCR1 antagonists as immunomodulatory agents
US6858744B2 (en) Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
MXPA00007690A (en) Novel dihydroxyhexanoic acid derivatives
NZ523610A (en) A method of treating inflammatory conditions in a non-human mammal comprising administration of dihydroxyhexanoic acid derivatives
CZ20002760A3 (cs) Nové deriváty dihydroxyhexanové kyseliny a farmaceutický prostředek, který je obsahuje
CN114516858A (zh) 一种DprE1酶抑制剂及其用途
US20040087797A1 (en) Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
JP2005527604A (ja) ジヒドロフラン２オン誘導体の製造方法
CZ9902904A3 (cs) Deriváty amidů heteroarylhexanových kyselin, farmaceutické kompozice na jejich bázi a způsoby léčení nebo prevence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee